David Nierengarten: Other Companies Have Similarly Sought to Target Eye Diseases but They Have Encountered More Challenges Then Expected.
Daniel Ives: This Would be a Major Shot in the Arm for Crypto if Apple Headed Down this Path
Michael Pachter: Amazon Doesn't Care if They Lose $30 Million They Do Care if They Alienate Filmmakers.
Daniel Ives: Hurricane-like Storm Over the Past Six Months as Cloudera Has Tried to Navigate a Choppy Hadoop Market
Daniel Ives: Hurricane-like Storm over Past Six Months as Cloudera tried to Successfully Integrate Hortonworks Deal while Navigating Choppy Hadoop Market.
Daniel Ives: The Video Capability on iPhone 11 Versions will be Significantly Stepped Up
Daniel Ives: Given Where Apple Strategically is Focused, a Move Into Crypto Could Make Sense
David Nierengarten: Stocks like Y-mAbs Therapeutics Which Have Advanced Assets as Well as Upside Potential
David Nierengarten: Y-mAbs Therapeutics Should be Particularly Attractive for Investors.
Robert Driscoll: Cidara's Partnership with Mundipharma is a Significant Positive